Abstract Aberrant DNA methylation is considered an important epigenetic mechanism for gene inactivation. Monoclonal gammopathy of undetermined significance (MGUS) is believed to be a precursor of multiple myeloma (MM). We have analyzed methylation status of p15 INK4B , p16
Introduction
Multiple myeloma (MM) is a clonal B-cell neoplasm characterized by atypical plasma cell infiltration in the bone marrow (BM) and the presence of monoclonal protein in serum and/or urine. The natural course of the disease may progress from monoclonal gammopathy of undetermined significance (MGUS) to MM. The transformation rate of MGUS to MM is about 1% per year with an actuarial probability of malignant evolution of 30% at 25 years. After a median of 10 years, about one quarter of MGUS patients develop MM [30] . During this process, multiple genetic alterations are sequentially acquired [23] .
There is increasing evidence that, in addition to genetic aberrations, epigenetic processes play a major role in carcinogenesis, particularly DNA methylation [12] . This modification is imposed only on cytosines that precede guanosines in the CpG dinucleotide. The distribution of the CpG dinucleotides in the genome is asymmetric, showing regions of the highest CpG content, called CpG islands, which are often associated with promoter region. In normal somatic cells, they are usually unmethylated to allow gene expression [2] .
In cancer cells, the pattern of methylation is altered. While global hypomethylation of the genome takes place [13] , there is a growing list of genes having abnormal methylation at promoter regions [11] . Thus, aberrant methylation of tumor suppressor genes (TSG) promoter regions is now considered an important epigenetic mechanism for gene inactivation [22] , in addition to deletion and point mutation. Like genome alterations, hypermethylation occurs in a nonrandom and tumor-type specific pattern [7] . In hematologic neoplasias, repression of gene transcription by aberrant promoter methylation affects genes that regulate different cellular pathways relevant to tumor development, such as cell cycle regulation, DNA repair, apoptosis, and growth factor response, providing a selective advantage to malignant cells, as do mutations.
In recent years, some reports have evaluated methylation status of TSG in different types of solid tumors and hematologic malignancies [3, 24] . However, there is scarce information about aberrant promoter methylation in MGUS. Among them, p16
INK4A gene was the most extensively evaluated in this pathology, showing a wide range of methylation frequencies (0-39%) [6, 17, 19, 33, 35, 44, 47] . On the contrary, there are very few information about p15 INK4B [19, 33, 44] and ARF [33, 44] , only one report for SOCS-1 [41] , RASSF1A, and TP73 [44] , while p27 KIP1 has not been evaluated in this entity.
ARF, p16 INK4A , and p15 INK4B genes are cell-cycle regulators located on chromosome 9p21, region that is frequently involved in human tumors. Their alterations results in loss of the normal cell cycle control, promoting malignant transformation [14, 32, 40] . In the same way, p27 KIP1 gene (12p13) is involved in G1-S transition, inhibiting cyclin-dependent kinase 2 (CDK2)-cyclin E and CDK2-cyclin A [48] . The TP73 gene, banded at 1p36.3, is homologue of the TP53 tumor suppressor. TAp73 is a TP73 isoform with tumor suppressor activity that induces apoptosis and cell-cycle arrest [36, 41] . RASSF1A (3p21.3) may mediate the apoptotic effects of RAS and induce cell cycle arrest by engaging the Rb family cell cycle checkpoint [45, 49] . SOCS-1 (16p13.2) is involved in growth-factor response. This gene is a suppressor of a wide variety of cytokines recently implicated in the negative regulation of IL-6 through direct interaction with JAK (Janus-activated kinase) proteins [27] . In the present study, we have analyzed the methylation status of these seven tumor-related genes in patients with MGUS and MM in order to determine the role of aberrant promoter methylation as one of the steps involved in the progression of MGUS to MM. Results were correlated with clinicopathologic characteristics of patients.
Material and methods

Patients
Twenty-one patients with MGUS and 44 with untreated MM were included. For all cases, these procedures were performed for diagnostic purposes, and all individuals provided their informed consent according to institutional guidelines. The study was approved by the Ethics Committee of our institution. The diagnosis was based on standard criteria [29] . MM staging was made following the Durie and Salmon criteria [9] and the recently developed International Staging System [18] . Median follow-up was 25.9 months (range 1-101 months). Clinicopathologic characteristics of all patients are summarized in Table 1 .
Methylation-specific polymerase chain reaction Genomic DNA was isolated from BM mononuclear cells. The methylation-specific polymerase chain reaction (MSP) was performed as previously described. Briefly, 1 μg of genomic DNA was denatured at 37°C for 20 min with 3 M NaOH and modified with 4.5 M sodium bisulfite (Sigma, St. Louis) and 10 mM Hydroquinone (Sigma, St Louis) at 55°C for 5 h. After purification with the Wizard TM DNA Clean-up System (Promega A7280, Madison, WI, USA), the DNA was desulfonated in 3 M NaOH. The subsequent PCR amplification was performed using primers designed for either methylated or unmethylated DNA (Table 2) . Primers used for ARF, p15 INK4B , and p16 INK4A genes were previously described [10, 21] . Primers for methylated and unmethylated remaining genes were designed taking into account the GeneBank sequences that include the promoter region of the genes TP73 (TAp73 isoform; AC136528), p27 KIP1 (AF480891) and RASSF1A (NC000003), and exon 2 of SOCS-1 (AF132440 (Table 2 ), 72°C 1 m extension, and 72°C 5 m final extension. In the analysis of each gene, we included four types of controls to ensure specificity: peripheral blood samples from ten normal individuals (normal control), CpGenome™ Universal Methylated DNA (Intergen, New York, USA) as positive control; cell lines HCT-116, RAJI, LoVo, and DLD-1; and template (water). Specificity was demonstrated when, for each gene, the M primers only yielded a band from positive control, the U primers produced a band from normal DNA, and none of the primers yielded any product in the absence of template or when nonbisulfite-treated DNA was used as template. Cell lines information about methylation status was obtained from the literature. To confirm the intact nature of the genomic DNA, MSP from patient samples was also performed with the specific primers for the unmethylated condition of each gene.
DNA sequencing
PCR products were purified in 2% agarose gels, sequenced bidirectionally, and analyzed on an automated DNA sequence analyzer (377 ABI Prism, PE Biosystem, Foster City, CA, USA). The specificity of the MSP was verified by DNA sequencing of methylated positive control. DNA sequence of methylated control DNA was aligned and compared with sequence of the wild-type DNA. Methylated cytosine residues in CpG dinucleotide remained as C, whereas unmethylated cytosines were changed to T after bisulfite conversion.
Statistical analysis
Groupwise comparison of the distribution of clinical and laboratory variables was performed with the Student's t test The methylation index (MI; ratio between the number of genes methylated and the number of genes analyzed) was also calculated.
Results
Methylation analysis
We have evaluated methylation status of p16 INK4A , p15 INK4B , ARF, p27 KIP1 , TP73, RASSF1A, and SOCS-1 genes in BM cells from patients with MGUS and MM using MSP assay, followed by sequencing analysis of the PCR products. DNA samples from ten healthy blood donors were also analyzed. None of the normal controls showed aberrant methylation of the evaluated genes. The positive and the negative controls showed the expected MSP results (normal DNA: U-MSP positive/M-MSP negative; methylated DNA: U-MSP negative/M-MSP positive).
In MGUS, the MI ranged from 0 to 0.43 with a median of 0.14, corresponding to one gene/sample; 66.7% of patients showed one to three genes aberrantly methylated (Fig. 1a) . The analysis of MM patients showed that MI ranged from 0 to 0.71 with a median of 0.29, corresponding to two genes per sample. The majority of samples (84.1%) showed methylation of at least one gene. Only one gene was affected in 27% cases, and 39% patients presented two methylated genes (Fig. 1b) . Whereas, the percentage of MGUS cases with at least one methylated gene was not statistically different to that of MM patients, the mean MI of MM was higher than that of MGUS (p<0.05).
Fourteen percent of MGUS patients showed SOCS-1 methylation, a frequency significantly lower than that observed in MM (52%; p=0.006). As for TP73, ARF, p15 INK4B , and p16 INK4A genes, their frequencies in MGUS were 33%, 29%, 29%, and 5%, respectively, comparable to that observed in MM (45%, 29%, 32%, and 7%, respectively). All MGUS patients showed unmethylated RASSF1A; meanwhile, this gene was methylated in only one MM patient. Both entities showed lack of methylation of p27 KIP1 gene. A statistical association in the pattern of methylation between p15 INK4B and TP73 genes was found in both pathologies (p=0.008 and p=0.04 for MM and MGUS, respectively; Figs. 1a, b) . Figure 2a shows MSP assays from the analyzed TSG. Authenticity of MSP was confirmed by sequencing methylated products. Representative sections of the sequencing analysis of different genes are shown in Fig. 2b .
Relation between methylation and clinicopathologic parameters
In both entities, methylation status and clinicopathological features, as described in Table 1 , were correlated. In MGUS Table S1 ; Fig. 3 ). In MM, methylation of p15 INK4B gene was more frequent in males (p=0.009) and in the IgG isotype (p=0.038), while the IgA isotype was only present in patients with unmethylated p15 INK4B gene (Fig. 4) . Survival analysis did not show differences in both OS and PFS between MM patients with or without methylation (p= 0.78 and p=0.98, respectively). RASSF1A and p16
INK4A
genes were not included in this evaluation due to the low number of cases with aberrant methylation. Data from ARF, SOCS-1, and TP73 are shown in Supplementary material (Table S2 ). There were no correlations between clinicopathologic characteristics and the total number of TSG methylated or the MI (Supplementary material, Table S3 ).
Discussion
There is strong evidence that DNA methylation plays a major role in silencing critical genes in cancer. In this study, we have evaluated methylation status of different TSG in MGUS patients and compared it with that of MM, by means of MSP followed by sequencing of the resulting product. MSP is a rapid and sensitive technique, currently Fig. 2 INK4A methylated and patient 1, unmethylated. M methylated reaction and U unmethylated reaction; Pos Positive control (CpGenome Universal Methylated DNA); Neg Negative control (water); MW molecular weight marker. Products' sizes are showed on the left. b Representative sections of the sequencing analysis of SOCS-1 (left) and TP73 (right) genes. The sequences of PCR unmethylated (I) and methylated products (II) were compared. In unmethylated samples (I), all cytosines were changed to thymines (asterisks). In methylated samples (II), cytosines in CpG dinucleotide remained cytosines (arrows) considered the standard for studying the methylation status of CpG islands in human cancer, especially if it is followed by the sequencing to confirm the identity of the methylated and unmethylated PCR products [16, 34, 43] .
Our data showed that epigenetic events are frequent in MGUS and MM. However, the extension of methylation, measured by the MI, was different between both entities, being MGUS significantly less methylated than MM. Nevertheless, this relatively high frequency of methylation in MGUS would be consistent with it being a premalignant condition. In agreement with our data, a previous report by Takahashi et al. [46] found no differences in the MI of MM from that of lymphoma or leukemias, but it was higher than that of MGUS. In addition, we did not find correlation between clinicopathologic features and MI, indicating that the extent of methylation would not be a prognostic factor for patients with plasma cell disorders.
SOCS-1 gene methylation was significantly more frequent in MM than in MGUS patients, suggesting the methylation of this gene as an important step in the clonal evolution from MGUS to MM. The only previous report [42] about SOCS-1 methylation studying MGUS and MM patients found comparable frequencies in both entities. Differences with our results could probably be explained by distinct clinicopathologic characteristics of MGUS patients included in both series, but the absence of these data in the report of Reddy et al. [42] makes this comparison impossible to do. SOCS-1 is an intracellular negativefeedback molecule that inhibits JAK-signal transducer and activator of transcription activation initiated by various stimuli, including IL-6. IL-6 is an essential growth and survival factor for tumor cells in MM [25] . In addition, it has been hypothesized that the dysregulation of cytokines might be involved in the transition from MGUS to MM [31, 39] . Thus, silencing of SOCS-1 by methylation may allow uncontrolled proliferation of plasma cells, promoting disease progression from MGUS toward MM.
In MGUS patients, ARF and p15 INK4B genes showed similar methylation frequencies. For ARF, we found a higher methylation frequency than those observed in the literature [33, 44] . While for p15 INK4B , our values were in the range of those previously reported [19, 33, 44] . Regarding p16
INK4A , the frequency of 5% observed in our series was comparable with the lowest results previously published [5, 35, 47] . In our series, methylation of p15
INK4B
was more frequent than that of p16 INK4A in agreement with those observed by Guillerm et al. [19] . In reference to TP73 gene, the literature showed only one report of TP73 methylation in MGUS patients [44] , describing a comparable frequency (21%) to those observed in our series (33%).
TP73, p16
INK4A , p15 INK4B , and ARF genes showed similar methylation frequencies in both MGUS and MM, suggesting that they are early events in the pathogenesis and development of plasma cell disorders and probably not involved in the progression from MGUS to MM.
In both entities, concurrent hypermethylation of p15 INK4B and TP73 was observed. This suggests that disruption of pRb/CDK4/6 pathway by p15 INK4B methylation and the prevention of apoptosis by TP73 methylation may collaborate with development of plasma cell disorders. Although the present association was not previously reported, concomitant methylation of p16 INK4A and p15 INK4B was found in 56% MM and 100% of plasmocytomas [38] E-cadherin, and Death-associated protein kinase were found in connection with plasma cell leukemia development [15] .
None MGUS patient had methylation of RASSF1A and p27 KIP1 gene. For RASSF1A, our results are discordant to the only description in the literature [44] that found a frequency of 14% for this pathology. In reference to p27 KIP1 gene methylation, there is no information about MGUS; meanwhile, Chim et al. [4] , like us, did not find methylation of this gene in MM patients. Simultaneously, Nakatsuka et al. [37] found 25% of non-Hodgkin lymphoma patients with methylation of this gene, but it was scarcely affected in other hematologic malignancies.
The correlation with clinicopathologic parameters in MGUS patients showed significant difference in mean age between patients with methylated or unmethylated SOCS-1 gene. Different data suggest that overall epigenetic modification is age-dependent. Wong et al. [50] found that frequencies of p15 INK4B and p16 INK4A methylation were higher in adult acute lymphoblastic leukemia than in children. In gastrointestinal tract, methylation begins in the normal colonic mucosa as an age-related event and progresses to hypermethylation in cancer [1] . Similar data were observed in prostate tissue. Although there are increasing methylation frequencies for RARβ2, RASSF1A, GSTP1, and ESR1 genes in normal prostate tissue with age, their methylation frequencies were higher in prostate cancer than in normal cells [28] .
The analysis of clinical data in MM showed an association of p15 INK4B methylation status with sex and IgG isotype, correlations that were not previously observed in other series. In addition, differences in OS and PFS between MM patients with and without hypermethylation were not statistically significant. In MM, some reports [15, 20, 35] found that OS was significantly lower in patients with methylated p16
INK4A gene, while others [16, 26, 44] showed no differences between methylated and unmethylated patients. Depil et al. [8] found that SOCS-1 gene methylation does not seem to influence the clinical outcome. In addition, although Seidl et al. [44] did not find statistically significant OS between MM patients with and without E-cadherin methylation, they found an association between E-cadherin methylation and poor prognostic markers.
Concluding, our results show a similar pattern of methylation of TP73, ARF, p15 INK4B , and p16 INK4A in MGUS and MM, with a concurrent methylation of p15 INK4B and TP73, supporting MGUS as a premalignant condition. Interestingly, SOCS-1 gene methylation was significantly more frequent in MM than MGUS, suggesting that methylation of this gene might be involved in the evolution from MGUS to MM. Silencing of SOCS-1 may result in greater responsiveness to cytokines, which may favor neoplastic development.
